Evidence map›Paper›PMID 42212111›Full record

ArticleJournal of human immunity2026

STAT2 R148 variant: A 16th-century founder mutation and clinical response to high-dose JAK inhibitor therapy.

Nima Parvaneh, Rasol Molatefi, Conor Gruber, Sajjad Biglari, Leila Moradi, Yoann Seeleuthner, Fatima Ailal, Ahmed Aziz Bousfiha, Neda Pak, Camille Soudée and 6 more

Abstract read
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nima ParvanehDivision of Allergy and Clinical Immunology, Department of Pediatrics, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3397-9716
Rasol MolatefiCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.ORCID https://orcid.org/0000-0002-3614-5039
Conor GruberDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-9102-8134
Sajjad BiglariFarin Genetics Laboratory, Tehran, Iran.ORCID https://orcid.org/0000-0002-8206-5515
Leila MoradiImmunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3768-7470
Yoann SeeleuthnerImagine Institute, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-1878-8567
Fatima AilalLaboratory of Clinical Immunology, Infection and Autoimmunity, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco.ORCID https://orcid.org/0000-0001-5824-3193
Ahmed Aziz BousfihaLaboratory of Clinical Immunology, Infection and Autoimmunity, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco.ORCID https://orcid.org/0000-0002-5011-9873
Neda PakRadiology Department, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3256-3364
Camille SoudéeImagine Institute, Paris Cité University, Paris, France.ORCID https://orcid.org/0009-0002-1445-7223
Jean-Laurent CasanovaImagine Institute, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-7782-4169
Jérémie RosainImagine Institute, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-2822-161X
Dusan BogunovicDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-9277-3232
Mohammad Reza FazlollahiImmunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-1454-3933
Mohammad ShahrooeiDr. Shahrooei Lab, Tehran, Iran.ORCID https://orcid.org/0000-0002-4974-3441
Jacinta BustamanteImagine Institute, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-3439-2482

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Genome-Wide Dissection of Mendelian Susceptibility to Mycobacterial DiseaseR37AI095983 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT · 2011 to 2020
$4.6M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R37 AI095983
6 · The paper itself

Abstract

STAT2 R148 variants cause severe type I interferonopathy by disrupting USP18-mediated negative feedback regulation. We studied two new Iranian patients homozygous for

Identifiers

PMID42212111
PMCPMC13215009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.